Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Apr 15;127(8):1220-1227.
doi: 10.1002/cncr.33367. Epub 2021 Jan 28.

Adherence to endocrine therapy including ovarian suppression: A large observational cohort study of US women with early breast cancer

Katherine E Reeder-Hayes  1   2 , Sophie E Mayer  3 , Jennifer L Lund  2   3
Affiliations
Free article
Observational Study

Adherence to endocrine therapy including ovarian suppression: A large observational cohort study of US women with early breast cancer

Katherine E Reeder-Hayes et al. Cancer. .
Free article

Abstract

Background: Recent clinical trials support adding ovarian suppression (OS) to oral endocrine therapy (ET) for premenopausal women with early breast cancer. The adoption of OS among real-world populations and the impact of OS on ET adherence have not been evaluated.

Methods: This study examined a retrospective, observational cohort of women under the age of 50 years with incident early breast cancer from 2001 to 2016. The IBM MarketScan Commercial insurance claims database was used to identify new users of ET with or without OS and to track discontinuation of or adherence to ET. In all, 21,948 women filled at least 1 prescription for ET within 12 months of their diagnosis after a washout period of 12 months with no prior claims. Patients who received an aromatase inhibitor without a synchronous OS drug were excluded.

Results: Use of OS increased over time and reached 11.3% in 2016. In an unadjusted analysis, 40.2% of ET+OS users discontinued ET early, whereas 48.8% of tamoxifen-alone users did. In adjusted analyses, ET+OS users had a similar likelihood of discontinuing ET in comparison with tamoxifen-alone users (hazard ratio, 0.92; 95% confidence interval, 0.83-1.03). Approximately 30% of women had low adherence over the first year of use. The likelihood of high adherence was similar, regardless of OS exposure.

Conclusions: The use of OS among young, commercially insured patients with breast cancer increased over time in agreement with recent clinical trial results but remained relatively low. Nonadherence to ET was common, but the use of OS was not associated with lower adherence to ET in this observational, nonrandomized cohort. These findings may reassure oncologists that use of OS does not endanger ET adherence, although prospective studies are needed for confirmation.

Keywords: breast cancer; endocrine therapy; observational cohort study; ovarian suppression; treatment adherence.

PubMed Disclaimer

Comment in

References

    1. Cuzick J, Ambroisine L, Davidson N, et al; LHRH-Agonists in Early Breast Cancer Overview Group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369:1711-1723.
    1. Dees EC, Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. Semin Oncol. 2001;28:322-331.
    1. Davidson NE. Ovarian ablation as treatment for young women with breast cancer. J Natl Cancer Inst Monogr. 1994;16:95-99.
    1. Ludwig Breast Cancer Study Group. Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J Clin Oncol. 1985;3:1059-1067.
    1. Yan S, Li K, Jiao X, Zou H. Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials. Onco Targets Ther. 2015;8:1433-1441.

Publication types

LinkOut - more resources